Vertex Pharmaceuticals Incorporated Announced The Us Food And Drug Administration (Fda) Approved Expanded Use Of Orkambi (Lumacaftor/Ivacaftor) To Include Children With Cystic Fibrosis (Cf) Ages 12 To <24 Months Who Are Homozygous For The F508Del Mutation (F/F Genotype) In The Cystic Fibrosis Transmembrane Conductance Regulator (Cftr) Gene. Orkambi Was Previously Approved By The Fda For Use In People With Cf Ages 2 Years And Older With Two Copies Of The F508Del Mutation.
